CD44 transmembrane glycoprotein is involved in angiogenesis, but it is not clear whether CD44 functions as a pro or antiangiogenic molecule. Here, we assess the role of CD44 in angiogenesis and endothelial proliferation by using Cd44null mice and CD44 silencing in human endothelial cells. We demonstrate that angiogenesis is increased in Cd44null mice compared to either wildtype or heterozygous animals. Silencing of CD44 expression in cultured endothelial cells results in their augmented proliferation and viability. The growth suppressive effect of CD44 is mediated by its extracellular domain and is independent of its hyaluronan binding function. CD44mediated effect on cell proliferation is independent of specific angiogenic growth factor stimulation. These results show that CD44 expression on endothelial cells constrains endothelial cell proliferation and angiogenesis. Thus, endothelial CD44 might serve as a therapeutic target both in the treatment of cardiovascular diseases, where endothelial protection is desired, as well as in cancer treatment, due to its antiangiogenic properties.
Introduction
Angiogenesis is a pathophysiological process involved in wound healing as well as tumor growth and metastasis. The switch of normally quiescent blood vessels to angiogenesis is determined by the balance of proangiogenic and antiangiogenic factors in tissue microenvironment. In tumors, endothelial cell (EC) proliferation and survival is regulated by growth factors such as VEGF, FGF2, or HGF, released either by tumor cells or normal cells in the tumor stroma. A survival benefit has been shown for blocking proangiogenic signaling by VEGF inhibitors in tumor therapy and continuation of such therapy beyond progression [1] . However, tumors can be intrinsically resistant to antiVEGF therapy or acquire resistance through different mechanisms during the therapy [2] . Better understanding of microenvironmental or ECspecific factors involved in the regulation of EC proliferation and blood vessel formation is needed to develop new more effective antiangiogenic tumor therapies. CD44 cellsurface glycoprotein has been shown to be necessary for efficient tumor vascularization [3] and to mediate induction of angiogenesis in response to hyaluronan (HA) oligomers [4] . CD44 mediates cell adhesion to its principal ligand HA via its Nterminal HA binding domain (HABD) [5, 6] . CD44 and HA interaction is important in the immune response where it mediates leukocyte rolling on HA during leukocyte recruitment into the inflammatory site [7] [8] [9] . CD44 also mediates HAinduced effects on vasculature. In vivo silencing of endothelial CD44 resulted in reduced vascular density of Matrigel plug implants in response to low molecular weight HA [4] . The interaction of CD44 with high molecular weight HA inhibits vascular smooth muscle cell proliferation, and CD44 deficiency has been shown to increase neointima formation after arterial injury [10] . Cd44null mice display reduced vascularization of Matrigel plugs containing CD44positive B16 melanoma cells, as well as reduced vessel density in B16 melanoma and ID8VEGF ovarian carcinoma xenografts [3] . However, the contribution of CD44 to in vivo angiogenesis has not been studied in Cd44null mice in less complex models using defined angiogenic growth factors instead of large numbers of tumor cells. We have previously shown that administration of recombinant soluble CD44 hyaluronan binding domain (HABD) inhibits in vivo angiogenesis in both VEGF and FGF2stimulated chick chorioallantoic membranes and tumor xenograft growth, and that in vitro, sCD44 HABD controls EC proliferation [11] . Significant levels of soluble CD44 have been reported in normal human serum and even higher levels in mouse serum. Increased serum levels of soluble CD44 (sCD44) have been linked to different pathological conditions, including cancer and type 2 diabetes [12] [13] [14] . Soluble CD44 is mainly a shedding product of membrane CD44 [15, 16] . If the hypothesis of the proangiogenic role of CD44 holds, recombinant soluble CD44 HABD should function as a decoy receptor for HA, the principal ligand of CD44. Nevertheless, we have previously found that the nonHA binding mutant of CD44 HABD showed similar antiangiogenic and tumor growth inhibitory functions [11] , suggesting that a mechanism other than HA binding might be involved.
The aim of the current study was to analyze the effects of Cd44 gene deficiency and nonHA binding CD44 HABD treatment on in vivo angiogenesis and in vitro EC proliferation to conclusively determine the role of CD44 in angiogenesis and in order to cast light upon the mode of action of the nonHAbinding CD44 HABD.
Results

Cd44null mice display increased angiogenic response
We studied angiogenesis in mice lacking CD44 (Cd44 / ). In a preliminary experiment, we assessed the invasion of isolectinB4 and CD105positive cells into the Matrigel plug in response to 50 ng/ml VEGF. Surprisingly, results indicated that plugs from Cd44 / mice contained more cells than plugs from wildtype mice (data not shown). We also tested capillary outgrowth in aortic fragments isolated from Cd44 / mice. Aortic fragment assay indicated apparently more robust outgrowth of capillarylike structures from CD44 / fragments compared to wildtypes (Supplemental Fig. 1 in Online Resource 1). This finding is in agreement with Chun et al. 2004 study [17] , showing no defect in capillary outgrowth and vessel morphogenesis in aortic fragments isolated from Cd44 / mice. In the following series of experiments, we used the directed in vivo angiogenesis assay [18] to quantitatively test FGF2/VEGFinduced angiogenic response in Cd44 / and wildtype mice of C57BL/6, C3H or mixed genetic backgrounds ( Fig. 1 ). We found a 5.4 ± 2.2fold increase in blood vessel invasion in response to FGF2/VEGF compared to unstimulated controls in Cd44 / mice of mixed genetic background (ttest: P = 0.048, N = 2 experiments, effect size 1.2 ± 0.45 [95% CI, 0.372.1]; Fig. 1A ). Angiogenesis induction in wildtype mouse strains compared to unstimulated controls was in C3H 1.4 ± 0.5fold (ttest: P = 0.41, effect size 0.081 ± 0.071 [95% CI, 0.0610.22]), C57BL/6 1.5 ± 0.62fold (P = 0.38, effect size 0.2 ± 0.17 [95% CI, 0.090.56]), and in wildtype mice of mixed genetic background 4.2 ± 1fold (ttest: P = 0.13, effect size 0.14 ± 0.039 [95% CI, 0.0820.2]; Fig. 1A ). The estimated effect size of growth factor stimulation was large in Cd44 / mice with confidence interval ranging from small to very large, whereas in wildtype mouse strains growth factor stimulation displayed small effect size with confidence intervals including zero. When comparing growth factor stimulated groups, Cd44 / mice displayed apparently severalfold higher blood vessel invasion into angioreactors in response to FGF2/VEGF than wildtype mice. These data suggest that Cd44 deficiency results in augmented angiogenic response. However, factors other than CD44 might also affect the efficiency of angiogenesis induction in mice of different genetic backgrounds [19] . To confirm increased angiogenesis in the absence of CD44, and to study the contribution of CD44 to neoangiogenesis in an inbred, genetically homogeneous background, we backcrossed Cd44 / mice for six generations to the C57BL/6 strain. Using littermate controls, we found that Cd44 genotype had a significant effect on angiogenesis induction (ANOVA, F 2,42 = 3.98, P = 0.026). Angiogenesis was increased in Cd44null animals compared to wildtype or heterozygous mice. FGF2/VEGF stimulation resulted in a 2.1 ± 0.5fold increase of blood vessel invasion in C57BL/6 Cd44 +/+ mice (oneway ANOVA, P = 0.03; effect size 0.39 ± 0.15 [95% CI, 0.0980.67]); in a 1.4 ± 0.24fold increase in their Cd44 +/ littermates (oneway ANOVA, P = 0.061; effect size 0.22 ± 0.1 [95% CI, 0.0190.4]); and in a 2.9 ± 0.75fold increase in their Cd44 / littermates (oneway ANOVA, P = 0.0039; effect size 0.96 ± 0.26 [95% CI, 0.451.5]); N = 8 mice per genotype from 2 independent experiments. Angiogenesis induction was associated with Cd44 genotype in the growth factorinduced group of mice (ANOVA, F 2,21 = 5.45, P = 0.012), whereas there was no difference in baseline vessel invasion between different Cd44 genotypes in the unstimulated group. Posthoc testing of pairwise differences indicated that Cd44 / mice displayed increased angiogenesis compared to either their Cd44 +/ or Cd44 +/+ littermates (Fig. 1B) . We conclude from these experiments that CD44 deficiency results in augmented angiogenesis induction; and thus CD44 functions as an endogenous angiogenesis inhibitor.
Recombinant CD44 nonHAbinding mutant Fcfusion protein inhibits angiogenesis in vivo
We studied whether increasing the dose of CD44 by systemic administration of its soluble analog could suppress angiogenesis. We have previously shown that bacterially expressed GSTtagged nonHAbinding CD44 (CD443MUT) inhibits angiogenesis in chick chorioallantoic membrane and subcutaneous tumor xenograft growth in mice [11] . Untagged and GSTtagged CD443MUT display very short serum halflife limiting their potential in vivo use [20] . Thus, in order to improve in vivo efficacy, we generated CD443MUT with a C terminal fusion of human IgG1 Fc region (CD443MUTFc). Regarding pharmacokinetic characterization of CD443MUTFc, its serum halflife after intravenous administration to rats was 17 min (Supplemental Fig. 2 in Online Resource 1). The volume of distribution of CD44 3MUTFc was 18% of total body weight (%TBW), suggesting improved biodistribution compared to untagged CD443MUT protein (1.8% TBW; [20] ). We tested the antiangiogenic effects of CD443MUTFc in athymic nude mice. The results showed that FGF2/VEGF stimulation led to a 4.5 ± 1.1fold increase of blood vessel invasion into angioreactors over the PBS treated control groups (ttest: P = 7.7e07; effect size 0.8 ± 0.15 [95% CI, 0.51.1]; Fig. 2B, C) . We observed that intraperitoneal treatment of mice with CD443MUTFc inhibited FGF2/VEGFinduced angiogenesis. In the treatment group receiving 25 mg/kg CD443MUTFc, angiogenesis was inhibited to the unstimulated basal level compared to the growth factorinduced PBS treatment group (ttest: P = 1.6e05; effect size 0.8 ± 0.16 [95% CI, 1.1-0.5]). Administration of 0.5 or 5 mg/kg CD443MUTFc also resulted in apparent angiogenesis inhibition, but the response was less robust (Fig. 2C ). For recombinant protein control treatments, we used irrelevant rhIgG mAb or rhIgGFc. Both these molecules were purified identically to CD443MUTFc. The 0.5 mg/kg CD443MUTFc treatment showed significant inhibitory effect compared to pooled 0.5 mg/kg rhIgG/rhIgGFc control treatment group (ttest: P = 0.034; effect size 0.5 ± 0.24 [95% CI, 00.9]). Mice receiving intraperitoneally 5 or 15 mg/kg doses of rhIgGFc showed similar angiogenic response as PBS and 0.5 mg/kg rhIgGFc control treatment groups, suggesting that the IgGFc portion of CD443MUTFc is not responsible for the effects observed. Together, our results show that systemic administration of CD443MUTFc effectively inhibits in vivo angiogenesis.
Soluble CD44 levels are not affected by angiogenesis
Serum levels of sCD44 are increased due to enhanced CD44 shedding in case of inflammation or tumor growth. Previous research suggests that serum sCD44 concentrations show substantial variability between different mouse strains, and are significantly reduced (< 1 μg/ml) in severely immunodeficient mice [21] . To assess the significance of sCD44 in angiogenic response, we determined sCD44 concentrations in the sera of different wildtype mouse strains, in Cd44 +/ mice, and in athymic nude mice. Sera from Cd44 / mice were used as negative controls. We found that serum concentrations of sCD44 were similar in athymic nude mice and in wildtype mouse strains ( Fig. 3A and Table 1 ). Soluble CD44 levels in Cd44 +/ animals were reduced on average by 35% (95% credible interval: 1653%) compared to Cd44 +/+ mice. To analyse whether sCD44 concentrations correlate with angiogenesis induction, we excluded Cd44 / mice and nude mice from the dataset. We found no correlation between relative blood vessel invasion and postexperiment serum levels of sCD44 ( Fig. 3B ). Next, we evaluated whether the induction of angiogenesis, rhIgGFc or systemic treatments with CD443MUTFc that we used in the in vivo angiogenesis model lead to changes in the serum levels of sCD44 in nude mice. This analysis showed that neither angiogenesis induction nor treatments had any effect on the serum concentrations of sCD44 in nude mice (ANOVA, F 11,32 = 0.975, P = 0.49; Fig. 3C ). It also revealed that there was no correlation between postexperiment serum concentrations of sCD44 and vessel invasion into angioreactors irrespective of experimental intervention ( Fig. 3D ).
CD443MUTFc inhibits endothelial cell proliferation and viability
To find out whether CD443MUTFcmediated inhibition of angiogenesis is caused by its effects on ECs, we tested CD443MUTFc in a cell proliferation assay. We used cells synchronized by serum starvation to model the initial stages of stimulation of quiescent endothelial cells ( Fig. 4A ). We applied different concentrations of CD443MUTFc to growth arrested HUVECs and released cells from arrest by stimulation with 25 ng/ml VEGF. Real time growth curves of untreated controls show that 25 ng/ml VEGF induces robust proliferation in HUVECs that is sustained for at least 72 h ( Fig. 4B, leftmost panel) . In contrast, CD443MUTFc treatment dosedependently suppressed 25 ng/ml VEGFstimulated HUVEC growth, compared to rhIgGFc control treatments (Fig. 4B) . The difference in growth kinetics between CD443MUTFc and rhIgGFc treatments became apparent approximately 24 h after VEGFinduced release of cells from arrest. After this timepoint, rhIgGFc controltreated cells continued to proliferate, but in CD443MUTFctreated wells cell density plateaued. Next, we used the same growth arrested HUVEC model in a cell proliferation and viability assay to compare CD443MUTFc efficacy in inhibiting cell proliferation stimulated by either FGF2, VEGF or HGF ( Fig. 4C to E). We used an endothelialspecific inhibitor of cell proliferation, fumagillin, as a positive control to define the maximum response in our assay. FGF2 and VEGF induced robust proliferation in growtharrested HUVECs, whereas HGFstimulation resulted in much lower cell proliferation ( Fig. 4C to E, left panels). Compared to rhIgGFc, CD443MUTFc dosedependently inhibited HGFstimulated proliferation with the maximum inhibition of 60% ± 12.6 after 72 h incubation. FGF2 or VEGFstimulated EC growth was inhibited less efficiently by CD44 3MUTFc when compared to rhIgGFc, as the growth was reduced by a maximum of 10.7% ± 2.4 and 13.9% ± 4.5, respectively ( Fig. 4B to E, and G). These results are in agreement with respective growth factor potencies to stimulate HUVEC proliferation, CD443MUTFc was less efficient in inhibiting FGF2 or VEGFinduced proliferation, and showed more efficacy in case of a weak inducer, HGF. CD44v6 interacts with VEGFR2 and MET [22] . Therefore, we tested whether CD443MUT Fc has any effect on the protein levels or activation of these receptors. Western blot analysis showed no change in either VEGFR2 or MET protein levels or receptor activation in response to CD443MUTFc (Supplemental Fig. 3 in Online Resource 1). This suggests that CD44 3MUTFc does not inhibit EC growth by direct targeting of growth factor receptor signaling pathways. Additionally, we tested the effect of CD443MUTFc on GDF2stimulated HUVECs (Fig. 4D ). Vascular quiescence factor GDF2 (BMP9) belongs to the TGFβ superfamily ligands and regulates angiogenesis via ALK1, a type 1 TGFβ receptor [23, 24] . As shown in the left panel of Fig. 4F , in our model GDF2 is strongly antimitotic and induces the cell cycle block. Compared to rhIgGFc control treatments, CD443MUTFc showed a dosedependent inhibitory effect on cell numbers in GDF2treated HUVECs with 79.6% ± 6.7 of maximum response ( Fig. 4F and G). To ascertain whether apoptosis contributes to CD443MUTFcinduced growth inhibition, we used Annexin VFITC staining. We found that upon release from serum starvation, the basal levels of apoptosis in the HUVEC population were inversely related to the growth factor potency to stimulate cell proliferation. In response to incubation with 12.64 μM (4.9 log 10 M) CD443MUTFc, the number of apoptotic cells relative to pooled control treatments was increased by 9% ± 5 in VEGF, 28% ± 14 in 10%FBS, 34% ± 6 in FGF2, 45% ± 12 in HGF, 46% ± 6 in GDF2stimulated cells. However, VEGF or FGF2induced cells were the most protected against apoptosis induced by CD443MUTFctreatment (Fig. 4H ). In contrast, GDF2mediated growth arrest enforced cells to undergo apoptosis and this trend was further increased by CD443MUTFc treatment. The observed increase in apoptosis from a relatively low basal level in response to CD443MUTFc treatment and its apparent correlation with growth factor potency to stimulate proliferation, suggest that apoptosis occurs secondary to CD443MUTFcmediated inhibition of cell proliferation. Collectively, our data show that CD443MUTFc inhibits EC proliferation.
CD44 is not involved in GDF2/ALK1dependent SMAD signaling
Several studies suggest that CD44 is associated with TGFβ signaling, since the cytoplasmic tail of CD44 directly interacts with SMAD1 [25] , CD44 forms a galectin9mediated complex with BMPR2 [26] , and HA induces CD44 to complex with TGFBR1 [27] . Given that CD44 3MUTFc treatment resulted in an enhanced growth inhibitory effect in GDF2arrested HUVECs, we wanted to test whether CD44 could be involved in GDF2 mediated SMAD activation. We studied pSMAD1/5 nuclear localization and SMAD1/5 target gene activation in response to GDF2 stimulation in CD44silenced HUVECs. CD44targeting siRNA (siCD44) transfection resulted in substantial CD44 protein or mRNA downregulation compared to nontargeting siRNA control (siNTP) (Supplemental Fig. 4 in Online Resource 1). Simultaneously, we detected a robust GDF2dependent pSMAD1/5 nuclear localization (Supplemental Fig. 4A and B in Online Resource 1) and an induction or repression of selected known SMAD1/5 target genes ID1, SMAD6, SMAD7 or cMYC, respectively (Supplemental Fig. 4C in Online Resource 1). Immunofluorescence analysis showed that the nuclear area or other size/shape parameters of cell nuclei did not differ between siCD44 or siNTP control silenced cells (data not shown). We found that silencing of CD44 did not affect the nuclear localization of pSMAD1/5 or SMAD1/5 target gene expression in response to GDF2 stimulation (Supplemental Fig. 4A to C in Online Resource 1). Next, we studied the effect of CD443MUTFc on SMAD1/5 signaling by using a BMP responsive element reporter (BRE). We found that BRE reporter activity in HUVECs was increased in response to GDF2 stimulation, but this response was not sensitive to either CD44silencing or CD443MUTFc treatment (Supplemental Fig. 5A in Online Resource 1). In line with this, Western blot analysis of GDF2 stimulated HUVECs treated with CD44 3MUTFc showed no change in pSMAD1/5 levels (Supplemental Fig. 5B in Online Resource 1). To test whether prolonged CD443MUTFc exposure in vivo could trigger changes in SMAD1/5mediated gene expression, we analysed lung tissue of nude mice from two angiogenesis experiments described in Fig. 2 for the expression of selected SMAD target genes. We found no changes in the expression levels of SMAD1/5 or NFκB target genes (Supplemental Fig. 5C in Online Resource 1). Together, these results suggest that neither CD44 nor CD443MUTFc are involved in GDF2 ALK1SMAD1/5 signaling in ECs.
CD44 silencing augments endothelial cell proliferation
Since angiogenesis assay results showed increased blood vessel invasion in Cd44 / mice and inhibition of this response by CD443MUTFc treatment, we wanted to test whether CD44 knockdown in ECs results in increased cell growth. To this end, we used siRNA transfected HUVECs that had been growth arrested by serum starvation. Growtharrested cells were released by the addition of either 20% FBS or different concentrations of VEGF or FGF2.
Realtime impedance measurements showed that compared to 5% FBS stimulation ( Fig. 5A , left), 20% FBS or growth factor supplementation released cells from the cellcycle block and stimulated their growth sustainably over 72 h ( Fig. 5A and C). We found that siCD44 transfected cells reached higher densities at 72 h than control siNTPtransfected cells. Augmented cell growth and higher cell density in siCD44transfected ECs at the end of the experiment was independent of type and concentration of the growth factor used for stimulation ( Fig. 5A , C and E). Endpoint quantitation of viable cells performed 72 h after release supported the impedance measurement results. siCD44transfected HUVECs displayed increased cell numbers over all tested growth factors and concentrations ( Fig. 5B and D). These data suggest that the effect of CD44 silencing on cell proliferation was additive to the stimulatory effect of growth factors. The additive effect of CD44 silencing on cell proliferation was further supported by the typical VEGF dosedependent flattening of the growth curve that was observed in case of VEGFstimulated HUVECs. In case of FGF2, such suppression did not occur, and cell density increased linearly with growth factor concentration within the range (8 to 79 ng/ml) tested. Western blot analysis showed that FGFR1, VEGFR2 or activated VEGFR2 levels were not affected in CD44silenced HUVECs ( Fig. 5G and Supplemental Fig. 3C in Online Resource 1). The initial proliferation rate of CD44silenced HUVECs after seeding and before serum deprivation was increased compared to nontargeting siRNA or untransfected controls, and CD44silenced cells reached higher cell density within this time frame (Supplemental Fig. 6A in Online Resource 1). Notably, vimentinsilenced (siVIM) HUVECs showed similar behavior to CD44silenced cells before serum starvation (Supplemental Fig. 6A in Online Resource 1). The observation that siCD44 or siVIMtransfected HUVECs reached higher cell density after seeding and before the start of serum starvation compared to siNTPtransfected or untransfected cells was confirmed by modeling impedance data for barrier formation (Supplemental Fig. 6B in Online Resource 1). The release of siCD44transfected cells from serum starvation by VEGF or FGF2 stimulation resulted in enhanced barrier reformation when compared to siNTP or siVIMtransfectants (Supplemental Fig. 6B in Online Resource 1). We also assessed the effect of siCD44 by treating cells arrested in the cell cycle G1 phase with antimitogenic factor GDF2. We found that GDF2 induces cell cycle block and a subsequent decline in cell density, plausibly because cells undergo apoptosis ( Fig. 4H ). Impedance measurements showed that CD44silencing did not rescue GDF2stimulated HUVECs from growth arrest and cell numbers declined over the course of the experiment (Fig. 5E ). However, the cell viability assay performed after impedance measurements showed that CD44silencing resulted in more surviving cells compared to controls and partially rescued the cells from GDF2induced cell cycle block ( Fig. 5F ). Nevertheless, the GDF2 dose dependent inhibitory trend persisted. Together, these experiments show that CD44 knockdown results in enhanced EC proliferation, irrespective of the specific growth factor used for stimulation. Furthermore, CD44silencing experiments are consistent with Cd44 / mice data and suggest increased proliferation and survival of CD44deficient ECs as a plausible cellular mechanism to enhance angiogenesis.
Discussion
Here, we report that CD44 cellsurface glycoprotein is a negative regulator of angiogenesis. We show that CD44 constrains endothelial cell proliferation. Our results suggest that in the regulation of cell proliferation, CD44 functions independently of specific growth factor signaling pathways.
Based on our experiments, we extend the functions of CD44 to include the control of EC proliferation and angiogenesis. We found that blood vessel invasion into tumor extracellular matrix in response to FGF2/VEGF stimulation was substantially increased in Cd44null mice. This effect is likely to be cellautonomous, as silencing of CD44 expression in cultured ECs also resulted in augmented cell proliferation. We suggest that CD44 functions downstream of mitogenic signaling. Griffioen et al. [28] have shown that CD44 is upregulated in response to FGF2 or VEGF stimulation in cultured ECs, and in activated tumor blood vessels in vivo. Thus, enhanced angiogenesis and cell proliferation in case of CD44 deficiency or downregulation suggest that CD44 mediates negative feedback signaling that constrains cell proliferation. CD44 knockdown in dermal fibroblasts results in the stabilization of PDGF βreceptor and sustained ERK activation in response to PDGFBB stimulation [29] . In our study, we show that intervening with CD44 function by silencing or CD443MUTFc has no effect on the activation of angiogenic growth factor receptors. However, we observed that the potency of CD443MUTFc to inhibit EC proliferation was inversely related to the potency of VEGF, FGF2 or HGF to induce EC proliferation and survival. Several earlier reports have shown involvement of CD44 in TGFβ signaling [25] [26] [27] . Therefore, we tested if CD44 functions in GDF2 signaling. We saw enhanced growth arrest and apoptosis of ECs in response to CD443MUTFc treatment in GDF2stimulated ECs. Nevertheless, our different in vitro experiments showed that GDF2mediated signaling is not affected by disrupting CD44 expression or increasing CD44 dose via CD443MUTFc. We conclude from these results that CD44 acts via a different mechanism than disrupting any specific growth factor pathways.
Plausibly, CD44mediated negative feedback signaling on cell proliferation is activated by CD44HA interaction. Binding of high molecular weight HA to CD44 controls proliferation of smooth muscle cells, and probably also other mesenchymal cell types, including ECs [10] . Kothapalli et al. [10] also showed that in Cd44null mice the response to arterial injury resulted in increased neointima formation and smooth muscle cell proliferation during vessel regeneration. We have previously shown that the nonHA binding mutant of CD44 was as effective as its wildtype counterpart in angiogenesis inhibition in the chick chorioallantoic membrane angiogenesis model [11] . Here, we show that systemic administration of soluble mutant CD44 HABD (CD443MUT) has an antiangiogenic effect in a mouse model of angiogenesis, thus CD443MUT functions similarly to endogeneous CD44. In this context, we were interested whether endogeneous soluble CD44 levels correlate with angiogenesis. Soluble CD44 levels are reduced in immuno deficient BALB/c.Xid mice with defective Bcell maturation, and in SCID mice with absence of functional T cells and B cells, suggesting that immune cellderived proteolytic activity is responsible for CD44 shedding [21] . In our angiogenesis assays, we observed that wild type mouse strains displayed much weaker angiogenic response than immuno deficient athymic nude mice. Given that nude mice carried normal Cd44 gene dose, but their sCD44 levels were not known, we assumed that elevated angiogenesis in nude mice, compared to wild type strains, could be related to decreased sCD44 levels. We found serum sCD44 levels to be normal in athymic nude mice, suggesting that the induction of angiogenesis is not related to serum sCD44 levels. Furthermore, as athymic nude mice lack T cells, this result suggests that a large proportion of serum sCD44 is generated by B celldependent activity.
The signaling pathway downstream of CD44 is not well understood. CD44 has been implicated in cell-cell contact inhibition in schwannoma cells by recruiting the NF2 tumor suppressor protein to the plasma membrane [30] . Thus, it is possible that CD44 silencing abolishes the function of NF2, which leads to loss of contact inhibition and increased proliferation. However, embryonic fibroblasts isolated from Cd44null mice still exhibit functional contact inhibition compared to cells from Nf2null mice, but Cd44null cells seem to display faster growth rates compared to wildtype cells [31] . Our impedancebased real time monitoring of cell proliferation suggests steadily increased growth rates of CD44 silenced ECs after release from serum starvation. We found that barrier formation, which is directly related to cell density, is apparently more robust in CD44silenced ECs after growth factor stimulation. This suggest that the mechanisms behind enhanced cell proliferation could be other than defective cell-cell adhesion.
Our in vivo findings contrast with previous works showing that CD44 absence or its downregulation in vivo results in reduced angiogenesis [3, 4] . Lennon et al. [4] studied the contribution of CD44 to HA oligomerinduced angiogenesis, and found that CD44 silencing in vivo resulted in inhibited angiogenesis in response to oligo HA. Cao et al. [3] used a relatively high number of rapidly growing B16 melanoma cells as a source of angiogenic growth factors in a Matrigel plug assay and allowed the blood vessels to grow for 5 days only. Nevertheless, tumor angiogenesis assays using two different cell lines with very different tumor growth kinetics, B16 melanoma and ID8VEGF ovarian carcinoma, still suggested considerable inhibition of tumor formation and reduced vascular density at tumor margins in Cd44null mice [3] . However, it is plausible that CD44negative ECs were inhibited in trans by CD44 that was present on tumor cells [3] . Here, we show that administration of exogeneous soluble CD44 inhibited in vivo angiogenesis and EC proliferation. We found that Cd44 heterozygous mice displayed angiogenesis at a similar level to wildtype animals, showing that Cd44 is not haploinsufficient and lower than normal amounts are still sufficient for controlling angiogenesis. Tumor angiogenesis is dependent on interactions between tumor cells and host tissue stroma, and such interactions might be compromised in Cd44null animals. Tumor cells recruit macrophages to promote angiogenesis. However, [3] showed that in case of Cd44null mice bone marrow reconstitution with wildtype bone marrow did not rescue the angiogenesis defect, suggesting that endothelial CD44 expression is important.
Cd44null mice develop normally and do not display apparent vascular abnormalities. We suggest that CD44 plays a nonredundant role in physiological angiogenesis. CD44mediated interactions after its upregulation in endothelial cells in response to growth factor stimulation restrain cell proliferation. This control may contribute to the robust shutdown of angiogenesis during wound repair. In case of tumors, CD44mediated control of angiogenesis might be overridden by a surplus of growth factors and increased shedding of CD44.
In summary, we conclude that CD44 functions as a negative regulator of angiogenesis. Therefore, systemic absence of CD44 expression in mice results in increased angiogenic response. Our results also demonstrate that soluble CD44 regulates angiogenesis by suppressing endothelial cell proliferation. Importantly, the antiangiogenic effect of CD44 is achieved independently of its HAbinding property. Together, our data suggest that CD44 is important in maintaining normal angiogenesis levels and targeting of CD44 can be utilized in antiangiogenesis treatment strategies for cancer or in other applications where angiogenesis modulation is desired.
Materials and Methods
Cells, Reagents and Primary Antibodies
HUVECs were obtained from Cell Applications, Inc., ECGS was from Millipore. VEGF165 was from Serotec; GDF2, HGF and FGF2 were from Peprotech. Lipofectamine RNAiMAX (LF) was from Life Technologies. Nontargeting pool siRNA, #D0018101005, human CD44 siRNA, #L009999000005, and human vimentin siRNA, #L003551000005 (ON TARGETplus SMARTpool) were from Thermo Fisher Scientific. siRNA target sequences are listed in Supplemental Methods section in Online Resource 1. jetPEIHUVEC transfection reagent was from Polyplustransfection SA. Annexin VFITC and annexin binding buffer were from BD Pharmigen. CellTiterGlo reagent was from Promega. Primary antibodies, dilution and source used in this study: antiCD44 (2C5) mouse mAb 1/1000 from R&D Systems, antiVEGFR2 rabbit mAb (55B11) 1/1500 and antiFGFR1 rabbit mAb (D8E4) from Cell Signaling Technology and antiGAPDH mouse mAb 1/10000 from Millipore, IM7 rat antimouse CD44 (MCA4703; AbD Serotec), rat antimouse CD44 KM81biotin (Abcam).
Production of CD443MUTFc
CD443MUT with Cterminal human IgG1Fc domain, recombinant human IgG1Fc domain (rhIgGFc) and irrelevant human IgG1 mAb were produced by Icosagen Cell Factory (Estonia). Cystatin S signal peptide sequence was added to the Nterminus of the CD44 3MUTFc cDNA and the gene was synthesized by Genewiz, Inc. The synthesized CD44 3MUTFc cDNA was cloned into RSVLTR promoter containing pQMCF5 expression vector (Icosagen Cell Factory). The resulting expression plasmids were transfected into CHOEBNALT85 cells (Icosagen Cell Factory) and the expressed Fcfusion proteins were purified by Protein G sepharose, followed by Superdex 200 gelfiltration chromatography. The purified CD443MUTFc had a monomeric molecular weight of approximately 60 kDa. The endotoxin level of the purified CD443MUTFc was < 10 EU/mg as determined by chromogenic Limulus amebocyte lysate test (Lonza).
CD443MUTFc serum halflife
F344/NCrHsd male rats were from Harlan, Netherlands. The rats carried a polyurethane round tipped jugular vein catheter for blood sampling (Harlan Laboratories Surgical Services). After the preserum blood sample was taken, rats were injected intravenously via the tail vein with 3 mg of CD443MUTFc in 1 ml volume. Blood samples were collected using the jugular vein catheter at different time points. Blood samples were held at 37°C for 30 min to allow clot formation, and then centrifuged at 1300×g for 10 min at RT. The supernatants were collected and stored at 20°C until assayed. For sandwich ELISA microwell plates were coated with mouse antihuman IgG1 antibody clone G171 (BD Biosciences). Blocking was performed with 1.5% BSA/PBS. Standards were stepdiluted (40 μg/ml -0 μg/ml) in 0.5% BSA/PBS supplemented with 5%, 2% or 1% rat serum. Samples taken at different time points (pre serum, from as soon as possible to 24 hours) were diluted 1:50 or 1:100 in 0.5% BSA/PBS solution and applied to wells. Biotin mouse antihuman IgG antibody clone G18145 (BD Biosciences) and streptavidinHRP were used for detection. Tetramethylbenzidine was used for color development. Concentration at time zero and halflife were estimated from two parameter exponential decay model with the function f(x)=d(exp(−x/e)), where d is the upper limit at x = 0, and e is the decay constant.
In Vivo Angiogenesis Assay
Animal experiments were conducted under the license of the Project Authorization Committee for Animal Experiments of the Ministry of Rural Affairs of the Republic of Estonia. We used the Directed in Vivo Angiogenesis Assay kit (DIVAA; Trevigen, USA) according to manufacturers instructions. For the angiogenesis assay, 20 μl angioreactors were filled with growth factorreduced basement membrane extract containing 1.4 ng/μl FGF2, 0.47 ng/μl VEGF and heparin for the induction of angiogenic response or an equal volume of PBS for uninduced controls. Angioreactors were implanted subcutaneously into the dorsolateral flank of 9weekold athymic NudeFoxn1/nu female mice (Harlan, Netherlands). Cd44null mice were of mixed inbred background (B6;129Cd44tm1Hbg/J), termed "Cd44KO mix". B6;129 hybrid mice "WT mix" were used as controls. C57BL/6 and C3H mice were obtained from Harlan, Netherlands. The experimental groups of wildtype and Cd44null mice comprised 811weekold female and male mice. In one experiment, the Cd44KO mix and the respective wildtype mice were 4043 weeks old. For the angiogenesis assay in the C57BL/6 genetic background, the Cd44null allele was backcrossed for six generations to C57BL/6 mice (Harlan, Netherlands); experimental groups contained an equal number of female and male littermates. Implantation was performed on both flanks and one or two angioreactors were inserted per flank into immune competent mice or nude mice, respectively. Nude mice were injected intraperitoneally every second day with CD443MUT Fc, irrelevant human IgG1 mAb, rhIgGFc or vehicle (PBS) during two weeks. Mice were sacrificed after 14 days from start of the experiment by carbon dioxide asphyxiation and angioreactors were dissected. The angioreactor contents were retrieved and the EC that had invaded the angioreactors were quantitated by FITCLectin (Griffonia simplicifolia lectin I) staining [32] . Cellbound fluorescence was measured at 485 nm excitation and 535 nm emission wavelengths using a microtiter plate reader (Tecan, Swizerland). Data from irrelevant human IgG1 mAb and rhIgG1Fc treatments were pooled for analysis. Raw fluorescence values from each experiment were scaled by dividing by their root mean square.
Mouse sCD44 ELISA
For quantification of the serum levels of sCD44 in nude mice from the DIVAA experiments, wildtype mice of different backgrounds (C3H, C57BL/6, mixed), and their Cd44null, heterozygous and wildtype littermates of the C57BL/6 background were used. For ELISA measurements 96well plates were coated with 50 ng IM7 Ab/well overnight (ON) at 4°C and blocked with 5% nonfat dry milk for 2 h at 37°C. After blocking, samples and standards (Recombinant Mouse CD44 Fc Chimera; R&D Systems) were incubated in wells for 30 min at 37°C. Bound sCD44 was detected by incubating the plate with KM81biotin Ab for 30 min at 37°C. For color development, Vectastain ABC (Vector Laboratories) and tetramethylbenzidine substrate were used. Absorbance was recorded at 450 nm using a microtiter plate reader (Tecan).
HUVEC Growth and Treatments
HUVECs (passage 46) were cultured in 20% FBS containing M199 medium supplemented with 4 mM Lglutamine, 50 μg/ml heparin, 10 mM Hepes, and 30 μg/ml ECGS. For treatments, HUVECs were seeded into 0.1% gelatincoated cell culture plates. After 24 h, the cells were starved ON in M199 media supplemented with 1% FBS, 25 mM Hepes and 4 mM Lglutamine. After starving, the cells were incubated with different concentrations of rhIgG Fc or CD443MUTFc in the 5% FBS containing HUVEC growth media (5% FBS, M199, 4 mM Lglutamine, 12.5 μg/ml heparin, 10 mM Hepes, and 7.5 μg/ml ECGS) for 1 h at 37°C; and thereafter, stimulated with 25 ng/ml VEGF165, 25 ng/ml FGF2, 10 ng/ml GDF2 or 63 ng/ml HGF. The cells were further grown for 48 or 72 h at 37°C.
Electric CellSubstrate Impedance Sensing Assay
Cell layer impedance was recorded by an ECIS Zθ instrument connected to a computer running an ECIS software version 1.2.169.0 (Applied Biophysics, USA). We used 96WE1+ PET plates, pretreated with 10 mM cysteine (Applied Biophysics, USA). HUVECs were seeded at a density of 5000 cells/well. The final media volume during treatments was 175 μl per well. Cell growth was monitored at seven frequencies in the range of 100064000 Hz. Each well was measured approximately four times per hour. To summarize different experiments, values for each experiment were binned by hours and hourly means were calculated. The release mark from serum starvation was set as time point zero. Hourly means of raw readings were normalized by dividing by the mean value of the first hour after time point zero.
Apoptosis and Cell Viability Assays
For the apoptosis assay HUVECs were cultured in 0.1% gelatincoated 24well plates at a density of 25000 cells/well. Annexin VFITC staining was performed according to manufacturer's protocol. Briefly, cells were incubated with 1:20 Annexin VFITC in 50 μl of annexinbinding buffer for 15 min at room temperature (RT) in the dark and analysed by FACS Calibur (BD Biosciences). For the cell viability assay, HUVECs were cultured in 0.1% gelatincoated white 96well cell culture plates (Greiner Bioone) at a density of 5000 cells/well. After treatments, the cells were incubated with the CellTiterGlo reagent (in a ratio of 1:1 of reagent volume to media) for 10 min at RT and luminescence was recorded using a microtiter plate reader. For analysis, raw luminescence values were minmax normalized. Curves were fitted using a five parameter logistic equation: $f(x) = Bottom + \frac{Top Bottom}{(1+\exp(HillSlope(\log(x)\log(EC50))))^S}$.
HUVEC Transfection with siRNAs
siRNA transfections were performed using PEI or LF and 30 nM siRNAs. Transfection reagents and siRNAs were separately diluted in serumfree DMEM (4500 mg/l glucose). Diluted siRNA and transfection reagents were mixed and the transfection complex was incubated for 1520 min at RT. The cells were transfected in 2% FBS and 4 mM Lglutamine containing DMEM (4500 mg/l glucose) for 3 h (PEI transfection) or 4 h (LF transfection) at 37°C. Then, the transfection media was replaced with 20% FBS HUVEC culture media and cells were further incubated for 24 h at 37°C. For impedance measurements, the transfected cells were plated out at a 5000 cells/well density into cysteine pretreated and gelatin coated 96WE1+ PET plates. After starving, cells were stimulated with different concentrations of GDF2, VEGF or FGF2 in 5% FBS containing HUVEC growth media. After 72 h of incubation, the CellTiterGlo reagent was added to cells for cell viability measurement.
Western Blot Analysis 48 h after siRNA transfection, the cells were lysed in RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS) containing protease inhibitor cocktail (Roche). The proteins (5 μg of total protein) were separated on 7.510% SDSPAGE gradient gel and transferred to PDVF membrane at 350 mA for 1.5 h. The membranes were blocked in 5% whey in 0.1% Tween20TBS (TBST) at RT for 1 h, followed by a primary Ab incubation ON at 4°C and subsequent HRPconjugated secondary Ab (Jackson Immunoresearch) incubation for 1 h at RT in 2% whey in TBST.
Statistical Analysis
We used R version 3.3.1 (20160621) for data analysis and graphs (for the complete list of packages see Supplemental Methods in Online Resource 1). The percentile confidence intervals were obtained using nonparametric bootstrap resampling on 1000 replications. Cohen's d effect sizes with bootstrap confidence intervals were calculated using the bootES 1.2 package. Bayesian credible intervals were obtained via the Markov chain Monte Carlo method using the rjags 4.6 package. Scaling was done by dividing raw data by their root mean square using the R function scale. The data are shown as mean ± SEM.
Electronic Supplementary Material
Supplemental Fig. 1 shows aortic fragment angiogenesis assay using aortic rings dissected from wildtype and Cd44 / mice. Supplemental Fig. 2 shows the CD443MUTFc serum half life curve. Supplemental Fig. 3 shows the effect of CD443MUTFc on angiogenic growth factor receptor activation. Supplemental Fig. 4 shows the immunofluorescence analysis of GDF2induced pSMAD1/5 nuclear localisation in CD44silenced HUVECs and transcription of SMAD target genes in CD44silenced HUVECs in response to GDF2 stimulation. Supplemental Fig. 5 shows the BMPresponsive element reporter activity of 10 ng/ml GDF2 stimulated HUVECs transfected with CD44 siRNA and treated with CD443MUTFc and in vivo expression of SMAD target genes in mice treated with CD443MUTFc. Supplemental Fig. 6 shows that CD44 silencing augments EC growth and EC barrier formation is functional. Supplemental Table 1 gives the list of primers used for realtime qPCR experiments. Supplemental Table 2 gives the list of siRNA target sequences. Supplemental Table 3 gives the list of loaded R packages to compile this document.
Abbreviations List
CD443MUT -CD44HABD nonHAbinding triplemutant EC -endothelial cell ECIS -Electric Cellsubstrate Impedance Sensing HA -hyaluronan HABD -hyaluronanbinding domain sCD44 -soluble CD44 CD44 knockdown augments EC growth. siRNA transfected HUVECs were plated onto 96well electrode arrays. After 24 h, the cells were starved in 1% FBS media overnight. After starving, the cells were released from cell cycle block by the addition of 20% FBS (A); 8 ng/ml, 25 ng/ml, or 79 ng/ml FGF2 or VEGF (C); and 2.5 ng/ml or 10 ng/ml GDF2 (E). Following stimulation, HUVEC growth was monitored by recording electrode impedance. Raw impedance readings are shown to allow direct comparison to endpoint measurements. N = 2 for 5% and 20% FBS, 25 ng/ml and 79 ng/ml FGF2, and 8 ng/ml and 25 ng/ml VEGF. 
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